The mRNA technology that allowed the world to receive coronavirus vaccines in record time is now demonstrating its power in a completely different field — oncology. If it was recently believed that pancreatic cancer was practically "invisible" to the immune system, modern research shows the opposite: personalized mRNA vaccines can force the body to recognize and attack even the most aggressive tumors.
A Major Breakthrough in Chicago
This month, the American Society of Clinical Oncology held a meeting in Chicago, which became a true showcase of achievements in the field of immunotherapy. More than 130 studies dedicated to cancer vaccines were presented at the event. This direction is considered one of the most dynamic in modern medicine.
Leading global pharmaceutical giants participated in the conference: BioNTech, Moderna, Merck, and Pfizer. Companies are actively testing mRNA-based drugs in nine major and medium-sized clinical trials. The focus is on lung, kidney, bladder, and pancreatic cancer. The first results of a large-scale confirmatory trial for the treatment of melanoma are expected later this year.
Personalization: The Key to Victory Over Tumors
The main difference between oncological mRNA vaccines and classic drugs lies in their individual approach. According to Reuters, the treatment process looks as follows: a tumor sample is taken from the patient, unique mutations are identified, and a vaccine is created specifically for their disease. The goal is to prevent recurrence by training the immune system to recognize specific cancer markers.
This approach allows bypassing a problem that scientists have faced for decades. In rare cases, some patients with pancreatic cancer survived because their immune system accidentally began to attack the tumor. The researchers' task was to make this phenomenon mass and controllable.
Success Story: From Theory to Practice
Ten years ago, Dr. Vinod Balachandran from the Sloan Kettering Cancer Center became one of the first to see the potential of mRNA for treating deadly types of cancer. He hypothesized that the technology could be used to create vaccines based on specific mutations found exclusively in patients' tumors after surgical intervention.
In December 2019, the first phase of clinical trials involving 16 patients began. During the study, a combination of chemotherapy, the immunotherapy drug Tecentriq from Roche, and a custom-made mRNA vaccine from BioNTech was tested. The drug was targeted at mutated proteins characteristic of individual tumors.
The results exceeded expectations. In April, at a meeting of the American Association for Cancer Research, Balachandran reported impressive data: of the eight patients with pancreatic cancer whose immune system responded to the vaccine, seven were still alive after six years. A global Phase 2 study involving 260 patients is currently underway, aimed at confirming these results in a larger sample.
Global Scale and Political Context
Despite the fact that the reduction of federal grants in the US creates obstacles for academic institutions, major pharmaceutical companies continue to move the technology forward. Trials are actively expanding in Europe and Asia. This is happening as US officials send contradictory signals about the benefits and safety of mRNA technologies.
Today, scientists are also working on applying this technology to treat rapidly growing brain cancer. The drug is administered intravenously to quickly stimulate the immune system. Given that the 5-year survival rate for this disease is less than 7%, the emergence of new effective treatment methods becomes a matter of life and death for thousands of patients.